الفهرس | Only 14 pages are availabe for public view |
Abstract Hepatocellular carcinoma (HCC) is one of the most frequent human malignant neoplasms and the cause of more than a quarter of a million deaths each year throughout the world. In Egypt, the annual proportion of HCC showed a significant rising trend from 4.0% in 1993 to 7.2% in 2002. Combined RFA and TACE, is a promising new modality for management of medium and large sized HCC, to obtain a large coagulation area and to achieve complete ablation. In this study we evaluated the efficacy of combined RFA followed by TACE in a single HCC of (5-7cm) in comparison to TACE alone, also to evaluate local progression rate, recurrence free survival rate and overall survival rate. In this study, all Egyptian patients presented to Tropical Medicine Department and Outpatient Hepatoma Clinic for early detection and management of hepatic tumors (HCC), Ain Shams University Hospitals, they were classified into; group I included 25 patients diagnosed as HCC on top of chronic liver disease underwent chemoembolization, their ages ranged between 42 and 70 years (mean 59.6 ± 8.1years) included 22 male patients (88%) and 3 female patients (12%), group II included 25 patients diagnosed as HCC on top of chronic liver disease underwent Radiofrequency ablation followed by Chemoembolization within 5 days. , their age ranged between 45 and 68 years (56.6 ± 6.9years) included 22 male patients (88%) and 3 female patients (12%). Patients in both groups were subjected to full history taking, thorough clinical examination and laboratory investigations including (complete blood picture, liver function tests, kidney function, hepatitis viral markers and alfa fetoprotein) together with abdominal ultrasonography (US) and triphasic spiral computed tomography (CT). Regarding the clinical manifestation, HCC was discovered accidentally in (26%) of patients, although (52%) of patient were complaining of easy fatigueability and (48%) of patients were complaining of dullacheing pain. As regards the past history and etiological factors of HCC; parenteral therapy for schistosomiasis was recorded in (80%) of patients, history of previous surgical operation was recorded in (66%) of patients and smoking was recorded in (54%) of patients. Also our study recorded that (98%) of patients were seropositive for HCV-Ab and (16%) of patients were seropositive for (HBsAg, HbcAb).After combined therapy (RFA-TACE), complete response (CR) was achieved in (100%) of patients with medium and large sized HCC and none of patients achieved partial response (PR) or progressive disease (PD), also the rate of objective response after 7 months was (84%). At the end of the follow up, there was slight fluctuation in Child-Pugh score, but there was improvement in the performance status in patients after combined therapy as patients with PST (0) were shifted from (56%) to (91%) and those with PST (1) were shifted from (44%) to (9.1%). Also patients with good follow up were (60%), while patients with tumor progression and treated with supportive medical treatment were (4%) after combined therapy. Total recurrence rate (local + distant recurrence) at one year was (36%) and local recurrence (local tumor progression) rate at 1 year was (16%) after RFA combined with TACE. So this combined therapy achieved better one year survival rate (88%) and one year recurrence-free survival rate (56%) than monotherapy (TACE alone). |